FibroBiologics (FBLG) Competitors

$11.35
-0.45 (-3.81%)
(As of 05/17/2024 08:53 PM ET)

FBLG vs. AMRN, RVNC, ORGO, ANRO, ACIU, TERN, NBTX, PGEN, KRRO, and VRCA

Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Amarin (AMRN), Revance Therapeutics (RVNC), Organogenesis (ORGO), Alto Neuroscience (ANRO), AC Immune (ACIU), Terns Pharmaceuticals (TERN), Nanobiotix (NBTX), Precigen (PGEN), Korro Bio (KRRO), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.

FibroBiologics vs.

Amarin (NASDAQ:AMRN) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

FibroBiologics has a net margin of 0.00% compared to FibroBiologics' net margin of -18.96%. Amarin's return on equity of 0.00% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-18.96% -9.48% -6.34%
FibroBiologics N/A N/A N/A

Amarin currently has a consensus target price of $1.08, suggesting a potential upside of 24.52%. Given FibroBiologics' higher possible upside, equities research analysts clearly believe Amarin is more favorable than FibroBiologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
FibroBiologics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

22.3% of Amarin shares are owned by institutional investors. 2.0% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, FibroBiologics had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for FibroBiologics and 2 mentions for Amarin. FibroBiologics' average media sentiment score of 0.36 beat Amarin's score of 0.34 indicating that Amarin is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
FibroBiologics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

FibroBiologics has lower revenue, but higher earnings than Amarin.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$306.91M1.16-$59.11M-$0.12-7.25
FibroBiologicsN/AN/A-$16.49MN/AN/A

Amarin received 842 more outperform votes than FibroBiologics when rated by MarketBeat users.

CompanyUnderperformOutperform
AmarinOutperform Votes
842
74.45%
Underperform Votes
289
25.55%
FibroBiologicsN/AN/A

Summary

Amarin beats FibroBiologics on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBLG vs. The Competition

MetricFibroBiologicsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$371.37M$6.95B$5.02B$7.92B
Dividend YieldN/A2.72%44.82%3.91%
P/E RatioN/A17.03151.7617.74
Price / SalesN/A313.472,357.1491.55
Price / CashN/A34.1134.3730.67
Price / Book-94.585.695.344.76
Net Income-$16.49M$135.74M$100.67M$214.83M
7 Day Performance10.84%5.47%117.53%4.95%
1 Month Performance11.82%8.60%124.73%9.31%
1 Year PerformanceN/A-1.61%134.78%11.07%

FibroBiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMRN
Amarin
0.2237 of 5 stars
$0.91
-1.1%
$1.08
+19.1%
-32.0%$373.63M$306.91M-7.58275Analyst Revision
RVNC
Revance Therapeutics
4.279 of 5 stars
$3.48
+4.8%
$11.50
+230.5%
-90.5%$363.49M$234.04M-0.96597Gap Up
High Trading Volume
ORGO
Organogenesis
3.5253 of 5 stars
$2.85
-3.7%
$4.83
+69.9%
-14.4%$377.17M$435.47M71.14862Gap Down
ANRO
Alto Neuroscience
2.0904 of 5 stars
$14.18
+0.6%
$32.33
+128.1%
N/A$381.08M$210,000.000.00N/AAnalyst Revision
ACIU
AC Immune
2.4914 of 5 stars
$3.58
+8.5%
$16.00
+346.9%
+59.0%$354.06M$16.48M-5.04133Gap Down
High Trading Volume
TERN
Terns Pharmaceuticals
3.7746 of 5 stars
$5.99
+1.7%
$14.94
+149.4%
-41.5%$387.43M$1M-4.7266
NBTX
Nanobiotix
1.618 of 5 stars
$7.29
+6.4%
$11.00
+50.9%
+55.5%$343.58M$39.18M0.00101Positive News
Gap Up
PGEN
Precigen
4.253 of 5 stars
$1.37
+1.5%
$10.00
+629.9%
+7.0%$341.02M$6.22M-3.51202Earnings Report
Analyst Revision
Gap Down
KRRO
Korro Bio
2.9347 of 5 stars
$50.05
-0.4%
$126.25
+152.2%
N/A$401.55M$14.07M-0.53101Analyst Revision
VRCA
Verrica Pharmaceuticals
4.323 of 5 stars
$9.49
-0.7%
$11.25
+18.5%
+46.0%$402.57M$5.12M-6.50100Gap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:FBLG) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners